Horizon Discovery

Horizon Discovery

Horizon Discovery combines deep scientific experience in translational research with a precision gene-editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined cell lines, in vivo models, custom cell line generation, molecular reference standards, and contract research services to over 1,000 academic, clinical and biopharmaceutical organizations.

-
Telephone:
Email:
Fax:
Address: Building 7100, IQ Cambridge, Waterbeach
Postcode: CB25 9TL
Country: United Kingdom
Website: http://www.horizondiscovery.com
Membership type:Founder Member

Horizon powers genomic research and translational medicine from sequence to treatment.

Horizon Discovery is a UK Biotechnology company founded in 2007, and built upon a 20 year heritage in oncology research, translational medicine and gene-editing.  The company’s unique history and experience has culminated in a precision gene-editing platform that incorporates rAAV, CRISPR and ZFN technologies.  Horizon is the only company that has access to such a broad range of tools, allowing any genome modification challenge to be addressed.

In total, Horizon offers over 16,000 products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.

In addition, Horizon provides custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, and contract research and custom screening services.

Horizon aspires to provide science-driven research solutions that lead to advancement in the understanding of the genetic basis of disease and better healthcare outcomes for patients, ultimately providing the tools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutations that define their disease.

Human Isogenic Cellular disease models (X-MAN)

Human Isogenic Cellular disease models (X-MAN)

Panel of ‘off-the-shelf’ isogenic cell-lines that model common genes that occur in human cancer, plus provide their perfectly matched normal genetic backgrounds as a reference.

Precision Genome editing

Using its precision gene-editing platform that incorporates rAAV, CRISPR and ZFN technologies, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.

Drug Discovery Toolbox

Molecular & Cellular Biology
In vitro Functional Assays & Pharmacological Validation
In vivo Functional Validation

Horizon Discovery Group delivers consistent strong growth

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, is positioned for additional scale following its transformational acquisition of GE Healthcare Dharmacon, Inc. The company has announced its interim results for the six months ended 30 June 2017.

27 September 2017Read in full

Horizon Discovery introduces OncoSpan, the world’s largest reference standard for oncology

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announces the launch of OncoSpan, a novel cell line-derived multiplex DNA Reference Standard to support the validation of Next Generation Sequencing (NGS) assays.

25 September 2017Read in full

Horizon Discovery launches genome-wide CRISPRi and CRISPRa screening services

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announces that it has expanded its functional genomic screening portfolio to include first-to-market CRISPRi (interference) and CRISPRa (activation) screening services.

18 September 2017Read in full

Horizon Discovery releases CHO genome sequence to drive innovation in bioproduction

Horizon Discovery, a global leader in the application of gene editing technologies, today announced it has released a complete, high-quality, well annotated sequence of its GS Knockout CHO-K1 bioproduction cell line. The sequence will be made available publicly via the Ensembl website at EMBL-EBI, to serve the community as a resource to drive research and innovation in bioproduction at Horizon and across the industry.

1 August 2017Read in full

Horizon Discovery Group plc acquires GE Healthcare Dharmacon, Inc. for $85 million

Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing technologies, today announces that it has entered into an agreement to acquire Dharmacon from General Electric Company for a total consideration of $85 million (£65 million), subject to a working capital adjustment at completion of the Acquisition (Completion).

19 July 2017Read in full

Horizon Discovery takes exclusive licence for novel gene editing technology platform

Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces the completion of licensing agreements with all joint patent holders to provide exclusive worldwide rights to a novel transposon-based gene editing technology platform.

5 July 2017Read in full

Horizon Discovery’s reference standards support assay development and clinical trial

Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces the use of its Reference Standards in a recent successful premarket approval application (PMA) filing with the US FDA for a companion diagnostic in oncology by a leading next generation sequencing company.

3 July 2017Read in full

Abcam plc extends licence and supply agreement with Horizon Discovery

Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces that Abcam plc, a global leader in the supply of research antibodies, has extended a pre-existing licence and supply agreement between the two companies by exercising an exclusivity provision for the period from July 2017 through June 2018.

29 June 2017Read in full

Horizon Discovery’s RNA reference standards endorsed for use in cancer research testing

Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today notes its complete RNA reference standards product range have been endorsed by Thermo Fisher Scientific for use in its Ion Ampliseq and Oncomine fusion assays for cancer research.

15 June 2017Read in full

Horizon Discovery announces progress of its gene and cell therapy platform

Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces progress of its gene and cell therapy platform for contract service and therapeutic applications. The new offering will make use of Horizon’s extensive suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem cells (iPSC) and primary human lymphocytes.

14 June 2017Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. ...
  12. 20